PROHANCE Side Effects

6965653-2 | Shock
on Aug 30, 2010 Female patient from JAPAN , 57 years of age, was diagnosed with liver scan and was treated with Prohance (View Usage). Patient experienced the following unwanted or unexpected effects: shock. Prohance dosage: .

6925146-5 | Nephrogenic Systemic Fibrosis
Patient was taking Prohance (View Usage). Patient had the following side effects: nephrogenic systemic fibrosis on Jul 22, 2010 from DENMARK Additional patient health information: Female patient , weighting 209.4 lb, was diagnosed with nuclear magnetic resonance imaging and. Prohance dosage: . During the same period patient was treated with SANDIMMUNE (View Sandimmune Review and Sandimmune Label ), FLAMAZINE (View Flamazine Review and Flamazine Label ), REMICADE (View Remicade Review and Remicade Label ), CORTICOSTEROIDS (View Corticosteroids Review and Corticosteroids Label ), DAPSON (View Dapson Review and Dapson Label ), PROTOPIC (View Protopic Review and Protopic Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), ANTIBIOTICS (View Antibiotics Review and Antibiotics Label ).

6882472-6 | Circulatory Collapse, Cough, Dyspnoea, Loss Of Consciousness
Adverse event was reported on Jul 19, 2010 by a Male patient taking Prohance (View Usage) (Dosage: ) was diagnosed with angiogram, arthralgia, back pain (What is back pain?), anxiety (What is anxiety?) and. Location: UNITED KINGDOM , weighting 198.4 lb, After Prohance was administered, patient had the following side effects: circulatory collapse, cough, dyspnoea, loss of consciousness. During the same period patient was treated with VALIUM (View Valium Review and Valium Label ).

6683298-9 | Circulatory Collapse, Cough, Dyspnoea, Loss Of Consciousness
on Apr 06, 2010 Male patient from UNITED KINGDOM , weighting 198.4 lb, was diagnosed with angiogram, arthralgia, back pain (What is back pain?), anxiety (What is anxiety?) and was treated with Prohance (View Usage). Patient experienced the following unwanted or unexpected effects: circulatory collapse, cough, dyspnoea, loss of consciousness. Prohance dosage: . During the same period patient was treated with VALIUM (View Valium Review and Valium Label ).


6557735-4 | Dyspnoea, Pharyngeal Oedema, Swollen Tongue, Urticaria
on Jan 28, 2010 Male patient from UNITED STATES , 56 years of age, weighting 225.0 lb, was diagnosed with nuclear magnetic resonance imaging and was treated with Prohance (View Usage). Patient had the following side effects: dyspnoea, pharyngeal oedema, swollen tongue, urticaria. Prohance dosage: 20 Cc Once 042. Patient was hospitalized.

6441676-7 | Renal Failure Acute
Patient was taking Prohance (View Usage). After Prohance was administered, patient had the following side effects: renal failure acute on Nov 06, 2009 from GERMANY Additional patient health information: Male patient , 40 years of age, was diagnosed with nuclear magnetic resonance imaging and. Prohance dosage: .

6422644-8 | Renal Failure Acute
Adverse event was reported on Oct 21, 2009 by a Male patient taking Prohance (View Usage) (Dosage: ) was diagnosed with nuclear magnetic resonance imaging and. Location: GERMANY , 40 years of age, Patient experienced the following unwanted or unexpected effects: renal failure acute.

6342596-9 | Renal Impairment
on Sep 01, 2009 Male patient from JAPAN , 80 years of age, was diagnosed with diagnostic procedure, hepatic neoplasm malignant, haematuria, angiogram and was treated with Prohance (View Usage). Patient had the following side effects: renal impairment. Prohance dosage: . During the same period patient was treated with TRANSAMIN (View Transamin Review and Transamin Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), I.V. SOLUTIONS (View I.v. Solutions Review and I.v. Solutions Label ), ADONA (View Adona Review and Adona Label ), PRIMOVIST (View Primovist Review and Primovist Label ), IOPAMIDOL (Little Over Three Vials (50ml) Were Given At One Time) (View Iopamidol Review and Iopamidol Label ). Patient was hospitalized.

6339636-X | Renal Impairment
on Aug 20, 2009 Male patient from JAPAN , 80 years of age, was diagnosed with diagnostic procedure, hepatic neoplasm malignant, haematuria, angiogram and was treated with Prohance (View Usage). After Prohance was administered, patient had the following side effects: renal impairment. Prohance dosage: . During the same period patient was treated with TRANSAMIN (View Transamin Review and Transamin Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), I.V. SOLUTIONS (View I.v. Solutions Review and I.v. Solutions Label ), ADONA (View Adona Review and Adona Label ), PRIMOVIST (View Primovist Review and Primovist Label ), IOPAMIDOL (Little Over Three Vials (50ml) Were Given At One Time) (View Iopamidol Review and Iopamidol Label ). Patient was hospitalized.

6287725-0 | Hypersensitivity
Patient was taking Prohance (View Usage). Patient experienced the following unwanted or unexpected effects: hypersensitivity on Jul 27, 2009 from UNITED STATES Additional patient health information: Male patient , 55 years of age, . Prohance dosage: .

6107226-X | Arthralgia, Back Pain, Blood Pressure Increased, Chondropathy, Connective Tissue Disorder, Contusion, Dermatitis, Ill-defined Disorder, Joint Destruction
Adverse event was reported on Mar 05, 2009 by a Male patient taking Prohance (View Usage) (Dosage: One Time, Iv Rt Hand) was diagnosed with nuclear magnetic resonance imaging and. Location: UNITED STATES , 65 years of age, weighting 175.0 lb, Patient had the following side effects: arthralgia, back pain (What is back pain?), blood pressure increased, chondropathy, connective tissue disorder (What is connective tissue disorder?), contusion, dermatitis, ill-defined disorder, joint destruction.

6033051-4 | Anaphylactoid Shock
on Aug 12, 2008 Female patient from UNITED STATES , 86 years of age, weighting 140.2 lb, was diagnosed with back pain (What is back pain?), nuclear magnetic resonance imaging and was treated with Prohance (View Usage). After Prohance was administered, patient had the following side effects: anaphylactoid shock. Prohance dosage: 13ml Qd Intravenous (not Otherwise Specified. Patient was hospitalized.

6033041-1 | Anaphylactoid Shock
on Aug 06, 2008 Female patient from UNITED STATES , 34 years of age, weighting 244.7 lb, was diagnosed with cerebrovascular accident, nuclear magnetic resonance imaging brain and was treated with Prohance (View Usage). Patient experienced the following unwanted or unexpected effects: anaphylactoid shock. Prohance dosage: 20ml Qd Intravenous (not Otherwise Specified. During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ), SENOKOT S (DOCUSATE SODIUM;SENNA ALEXANDRINA) (View Senokot-s (docusate Sodium;senna Alexandrina) Review and Senokot-s (docusate Sodium;senna Alexandrina) Label ), LOVENOX (View Lovenox Review and Lovenox Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), SODIUM CHLORIDE 0.9% (View Sodium Chloride 0.9% Review and Sodium Chloride 0.9% Label ), LABETALOL HCL (View Labetalol Hcl Review and Labetalol Hcl Label ), MILK OF MAGNESIA TAB (View Milk Of Magnesia Tab Review and Milk Of Magnesia Tab Label ).

6033033-2 | Anaphylactoid Reaction, Cardiac Arrest
Patient was taking Prohance (View Usage). Patient had the following side effects: anaphylactoid reaction, cardiac arrest (What is cardiac arrest?) on Jul 03, 2008 from UNITED STATES Additional patient health information: Male patient , 74 years of age, weighting 220.5 lb, was diagnosed with nuclear magnetic resonance imaging and. Prohance dosage: 3ml Qd Intravenous (not Otherwise Specified. Patient was hospitalized.

6032947-7 | Hypersensitivity
Adverse event was reported on Mar 20, 2008 by a Male patient taking Prohance (View Usage) (Dosage: 20ml Qd Intravenous) was diagnosed with multiple sclerosis (What is multiple sclerosis?), nuclear magnetic resonance imaging brain and. Location: UNITED STATES , 41 years of age, After Prohance was administered, patient had the following side effects: hypersensitivity. Patient was hospitalized.

6032939-8 | Cardiac Arrest, Discomfort, Endocardial Fibrosis, Joint Contracture, Metaplasia, Mobility Decreased, Muscle Contracture, Myocardial Fibrosis
on Feb 27, 2008 Male patient from UNITED STATES , child 11 years of age, weighting 77.16 lb, was diagnosed with nuclear magnetic resonance imaging and was treated with Prohance (View Usage). Patient experienced the following unwanted or unexpected effects: cardiac arrest (What is cardiac arrest?), discomfort, endocardial fibrosis, joint contracture, metaplasia, mobility decreased, muscle contracture, myocardial fibrosis. Prohance dosage: . During the same period patient was treated with MULTIHANCE (View Multihance Review and Multihance Label ), MAGNEVIST (7ml X/day, 10ml X/day, 7.6ml) (View Magnevist Review and Magnevist Label ), OMNISCAN (X/day 8ml X/day, 8.8ml X/day, X/day, 8ml X/day, X/day, X/day) (View Omniscan Review and Omniscan Label ). Patient was hospitalized and became disabled.

6032937-4 | Nephrogenic Systemic Fibrosis
on Sep 09, 2008 Male patient from UNITED STATES , 71 years of age, weighting 209.4 lb, was diagnosed with angiogram, nuclear magnetic resonance imaging and was treated with Prohance (View Usage). Patient had the following side effects: nephrogenic systemic fibrosis. Prohance dosage: Intravenous (not Otherwise Specified), Intravenous (not Otherwise Specified). During the same period patient was treated with OMNISCAN (View Omniscan Review and Omniscan Label ), CONTRAST PRODUCT (View Contrast Product Review and Contrast Product Label ), GADOLINIUM PRODUCT (View Gadolinium Product Review and Gadolinium Product Label ), OMNIPAQUE 350 (View Omnipaque 350 Review and Omnipaque 350 Label ), OMNIPAQUE 300 (View Omnipaque 300 Review and Omnipaque 300 Label ).

6032933-7 | Nephrogenic Systemic Fibrosis
Patient was taking Prohance (View Usage). After Prohance was administered, patient had the following side effects: nephrogenic systemic fibrosis on Sep 09, 2008 from UNITED STATES Additional patient health information: Male patient , 59 years of age, weighting 165.3 lb, was diagnosed with nuclear magnetic resonance imaging brain and. Prohance dosage: Intravenous (not Otherwise Specified). During the same period patient was treated with MAGNEVIST (View Magnevist Review and Magnevist Label ), OMNISCAN (36ml Intravenous (not Otherwise Spcified)) (View Omniscan Review and Omniscan Label ), ZYLOPRIM (ALLOPURINOL) (NI) (View Zyloprim (allopurinol) (ni) Review and Zyloprim (allopurinol) (ni) Label ), ZANTAC (RANTIDINE HYDROCHLORIDE) (NI) (View Zantac (rantidine Hydrochloride) (ni) Review and Zantac (rantidine Hydrochloride) (ni) Label ). Patient was hospitalized and became disabled.

6032919-2 | Hypersensitivity
Adverse event was reported on Feb 29, 2008 by a Female patient taking Prohance (View Usage) (Dosage: 2ml Qd Intravenous (not Otherwise Specified)) was diagnosed with nuclear magnetic resonance imaging brain abnormal and. Location: UNITED STATES , 77 years of age, weighting 218.3 lb, Patient experienced the following unwanted or unexpected effects: hypersensitivity. During the same period patient was treated with LASIX (View Lasix Review and Lasix Label ), TOPROL (METROPROLOL SUCCINATE) (View Toprol (metroprolol Succinate) Review and Toprol (metroprolol Succinate) Label ), LIPITOR (View Lipitor Review and Lipitor Label ), ATIVAN (View Ativan Review and Ativan Label ), PLAVIX (View Plavix Review and Plavix Label ), ASPIRIN (ACETYLSALICYLIC ACID; PSEUDOEPHEDRINE HYDROCHLORIDE) (View Aspirin (acetylsalicylic Acid; Pseudoephedrine Hydrochloride) Review and Aspirin (acetylsalicylic Acid; Pseudoephedrine Hydrochloride) Label ).

6032911-8 | Anaphylactic Shock, Respiratory Distress
on Jan 17, 2008 Female patient from UNITED STATES , 54 years of age, weighting 158.3 lb, was diagnosed with nuclear magnetic resonance imaging and was treated with Prohance (View Usage). Patient had the following side effects: anaphylactic shock, respiratory distress. Prohance dosage: 15ml Qd Intravenous. Patient was hospitalized.

6032892-7 | Anaphylactoid Reaction
on Nov 20, 2007 Female patient from UNITED STATES , 55 years of age, weighting 116.8 lb, was diagnosed with angiogram, pulse absent and was treated with Prohance (View Usage). After Prohance was administered, patient had the following side effects: anaphylactoid reaction. Prohance dosage: 40ml Once Intravenous. Patient was hospitalized.

6032864-2 | Anaphylactic Reaction
Patient was taking Prohance (View Usage). Patient experienced the following unwanted or unexpected effects: anaphylactic reaction on Dec 12, 2007 from UNITED STATES Additional patient health information: Female patient , 68 years of age, was diagnosed with angiogram, intermittent claudication and. Prohance dosage: 60ml Once Intravenous.

6032859-9 | Chest Pain
Adverse event was reported on Oct 27, 2008 by a Male patient taking Prohance (View Usage) (Dosage: 17ml Qd Intravenous) was diagnosed with nuclear magnetic resonance imaging brain and. Location: UNITED STATES , 68 years of age, Patient had the following side effects: chest pain (What is chest pain?). During the same period patient was treated with NITRO PATCH (GLYCERYL TRINITRATE) (View Nitro-patch (glyceryl Trinitrate) Review and Nitro-patch (glyceryl Trinitrate) Label ), ISOSORBIDE DINITRATE (View Isosorbide Dinitrate Review and Isosorbide Dinitrate Label ). Patient was hospitalized.

6032831-9 | Anxiety, Stress, Syncope
on Oct 03, 2008 Female patient from UNITED STATES , 48 years of age, was diagnosed with nuclear magnetic resonance imaging, pituitary cyst and was treated with Prohance (View Usage). After Prohance was administered, patient had the following side effects: anxiety (What is anxiety?), stress (What is stress?), syncope. Prohance dosage: 20ml Qd Intravenous. During the same period patient was treated with FLEXERIL (View Flexeril Review and Flexeril Label ), TRAZODON (TRAZODONE HYDROCHLORIDE) (View Trazodon (trazodone Hydrochloride) Review and Trazodon (trazodone Hydrochloride) Label ), WELLBUTRIN (View Wellbutrin Review and Wellbutrin Label ), PAXIL (View Paxil Review and Paxil Label ), GEODON (ZIPRASIDONE HYDROCHLORIDE) (View Geodon (ziprasidone Hydrochloride) Review and Geodon (ziprasidone Hydrochloride) Label ). Patient was hospitalized.

6032829-0 | Nephrogenic Systemic Fibrosis
on Sep 09, 2008 Male patient from UNITED STATES , 71 years of age, weighting 209.4 lb, was diagnosed with nuclear magnetic resonance imaging, angiogram and was treated with Prohance (View Usage). Patient experienced the following unwanted or unexpected effects: nephrogenic systemic fibrosis. Prohance dosage: Intravenous, Intravenous. During the same period patient was treated with OMNISCAN (View Omniscan Review and Omniscan Label ), PROZAC (View Prozac Review and Prozac Label ), DOCUSATE (DOCUSATE) (View Docusate (docusate) Review and Docusate (docusate) Label ).

6032826-5 | Nephrogenic Systemic Fibrosis
Patient was taking Prohance (View Usage). Patient had the following side effects: nephrogenic systemic fibrosis on Sep 09, 2008 from UNITED STATES Additional patient health information: Male patient , 59 years of age, weighting 165.3 lb, was diagnosed with nuclear magnetic resonance imaging brain, venogram renal, renal arteritis and. Prohance dosage: Intravenous. During the same period patient was treated with MAGNEVIST (View Magnevist Review and Magnevist Label ). Patient was hospitalized and became disabled.

6032822-8 | Nephrogenic Systemic Fibrosis
Adverse event was reported on Sep 09, 2008 by a Male patient taking Prohance (View Usage) (Dosage: Intravenous) was diagnosed with nuclear magnetic resonance imaging and. Location: UNITED STATES , 48 years of age, weighting 205.0 lb, After Prohance was administered, patient had the following side effects: nephrogenic systemic fibrosis. During the same period patient was treated with MAGNEVIST (View Magnevist Review and Magnevist Label ), RENAGEL (View Renagel Review and Renagel Label ), PHOSLO (View Phoslo Review and Phoslo Label ), LOMOTIL (View Lomotil Review and Lomotil Label ), TEMAZEPAM (View Temazepam Review and Temazepam Label ), INSULIN (INSULIN) (View Insulin (insulin) Review and Insulin (insulin) Label ), ACCUPRIL (View Accupril Review and Accupril Label ), CATAPRES PATCH (CLONIDINE) (View Catapres Patch (clonidine) Review and Catapres Patch (clonidine) Label ). Patient was hospitalized and became disabled.

6032818-6 | Anaphylactic Reaction
on Aug 18, 2008 Female patient from UNITED STATES , 73 years of age, was diagnosed with nephrectomy, nuclear magnetic resonance imaging and was treated with Prohance (View Usage). Patient experienced the following unwanted or unexpected effects: anaphylactic reaction. Prohance dosage: 15ml Qd. During the same period patient was treated with PROTONIX (View Protonix Review and Protonix Label ), ALPRAZOLAM (View Alprazolam Review and Alprazolam Label ), CRESTOR (View Crestor Review and Crestor Label ), LISINOPRIL (View Lisinopril Review and Lisinopril Label ), PROCARDIA (View Procardia Review and Procardia Label ), MICARDIS (View Micardis Review and Micardis Label ), ISOSORBIDE (ISOSORBIDE) (View Isosorbide (isosorbide) Review and Isosorbide (isosorbide) Label ). Patient was hospitalized.

6032735-1 | Cardiac Valve Disease, Discomfort, Fibrosis, Metaplasia, Mobility Decreased, Muscle Contracture, Myocardial Fibrosis, Nephrogenic Systemic Fibrosis, Pain
on Feb 27, 2008 Male patient from UNITED STATES , child 11 years of age, weighting 77.16 lb, was diagnosed with nuclear magnetic resonance imaging and was treated with Prohance (View Usage). Patient had the following side effects: cardiac valve disease, discomfort, fibrosis, metaplasia, mobility decreased, muscle contracture, myocardial fibrosis, nephrogenic systemic fibrosis, pain (What is pain?). Prohance dosage: . During the same period patient was treated with MULTIHANCE (View Multihance Review and Multihance Label ), MAGNEVIST (7ml X/day, 10ml X/day, 7.6ml) (View Magnevist Review and Magnevist Label ), OMNISCAN (8ml X/day, 8.8ml X/day, 8ml X/day) (View Omniscan Review and Omniscan Label ). Patient was hospitalized and became disabled.

6032710-7 | Nephrogenic Systemic Fibrosis
Patient was taking Prohance (View Usage). After Prohance was administered, patient had the following side effects: nephrogenic systemic fibrosis on Sep 09, 2008 from UNITED STATES Additional patient health information: Male patient , 48 years of age, weighting 205.0 lb, was diagnosed with nuclear magnetic resonance imaging and. Prohance dosage: Intraveneous (not Otherwise Specified). During the same period patient was treated with MAGNEVIST (View Magnevist Review and Magnevist Label ), RENAGEL (View Renagel Review and Renagel Label ), PHOSLO (View Phoslo Review and Phoslo Label ), LOMOTIL (View Lomotil Review and Lomotil Label ), TEMAZEPAM (View Temazepam Review and Temazepam Label ), INSULIN (INSULIN) (View Insulin (insulin) Review and Insulin (insulin) Label ), ACCUPRIL (View Accupril Review and Accupril Label ), CATAPRES PATCH (CLONIDINE) (View Catapres Patch (clonidine) Review and Catapres Patch (clonidine) Label ). Patient was hospitalized and became disabled.

5977127-6 | Granuloma, Nephrogenic Systemic Fibrosis
Adverse event was reported on Nov 25, 2008 by a Female patient taking Prohance (View Usage) (Dosage: ) was diagnosed with nuclear magnetic resonance imaging brain, angiogram, nuclear magnetic resonance imaging abdominal and. Location: UNITED STATES , weighting 189.6 lb, Patient experienced the following unwanted or unexpected effects: granuloma, nephrogenic systemic fibrosis. During the same period patient was treated with OMNISCAN (View Omniscan Review and Omniscan Label ), ALPRAZOLAM (View Alprazolam Review and Alprazolam Label ), CALCIUM (View Calcium Review and Calcium Label ), ESTROGEN NOS (View Estrogen Nos Review and Estrogen Nos Label ), FERROUS SULFATE TAB (View Ferrous Sulfate Tab Review and Ferrous Sulfate Tab Label ).

5938474-7 | No Adverse Event
on Oct 02, 2008 Male patient from GERMANY , 45 years of age, was diagnosed with diagnostic procedure and was treated with Prohance (View Usage). Patient had the following side effects: no adverse event. Prohance dosage: . During the same period patient was treated with OMNISCAN (View Omniscan Review and Omniscan Label ), MAGNEVIST (View Magnevist Review and Magnevist Label ).

5929262-6 | Cough, Depressed Level Of Consciousness, Lethargy, Urticaria
on Oct 23, 2008 Male patient from UNITED STATES , weighting 175.0 lb, was diagnosed with nuclear magnetic resonance imaging and was treated with Prohance (View Usage). After Prohance was administered, patient had the following side effects: cough, depressed level of consciousness, lethargy, urticaria. Prohance dosage: 20 Ml 1. Patient was hospitalized.

5929124-4 | Cough, Dyspnoea, Nasal Congestion, Sneezing, Throat Tightness
Patient was taking Prohance (View Usage). Patient experienced the following unwanted or unexpected effects: cough, dyspnoea, nasal congestion, sneezing, throat tightness on Oct 23, 2008 from UNITED STATES Additional patient health information: Female patient , weighting 250.0 lb, was diagnosed with nuclear magnetic resonance imaging and. Prohance dosage: 20 Ml Injected 1. Patient was hospitalized.

5918535-9 | Metastases To Lymph Nodes, Renal Failure Acute, Stasis Dermatitis
Adverse event was reported on Oct 03, 2008 by a Male patient taking Prohance (View Usage) (Dosage: ) was diagnosed with nuclear magnetic resonance imaging brain, diagnostic procedure, metastases to lymph nodes and. Location: JAPAN , weighting 123.5 lb, Patient had the following side effects: metastases to lymph nodes, renal failure acute, stasis dermatitis. During the same period patient was treated with MEGLUMINE GADOPENTETATE (View Meglumine Gadopentetate Review and Meglumine Gadopentetate Label ), FLOMOX (View Flomox Review and Flomox Label ), LOXONIN (View Loxonin Review and Loxonin Label ), DIGOXIN /00017701/ (View Digoxin /00017701/ Review and Digoxin /00017701/ Label ), WARFARIN SODIUM (View Warfarin Sodium Review and Warfarin Sodium Label ), CELESTAMINE /00252801/ (View Celestamine /00252801/ Review and Celestamine /00252801/ Label ), SELBEX (View Selbex Review and Selbex Label ).

5719271-4 | Nephrogenic Systemic Fibrosis
on Apr 18, 2008 Male patient from GERMANY , weighting 156.5 lb, was diagnosed with diagnostic procedure, multiple myeloma (What is multiple myeloma?) and was treated with Prohance (View Usage). After Prohance was administered, patient had the following side effects: nephrogenic systemic fibrosis. Prohance dosage: . During the same period patient was treated with MAGNEVIST (View Magnevist Review and Magnevist Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), THALIDOMIDE (View Thalidomide Review and Thalidomide Label ).

5627067-7 | Anaphylactoid Reaction
on Nov 30, 2006 Female patient from UNITED STATES , 51 years of age, weighting 170.4 lb, was diagnosed with mass, nuclear magnetic resonance imaging and was treated with Prohance (View Usage). Patient experienced the following unwanted or unexpected effects: anaphylactoid reaction. Prohance dosage: 15 Ml Once Iv.

5627066-5 | Anaphylactoid Reaction, Chest Pain, Convulsion
Patient was taking Prohance (View Usage). Patient had the following side effects: anaphylactoid reaction, chest pain (What is chest pain?), convulsion on Dec 20, 2006 from UNITED STATES Additional patient health information: Male patient , 42 years of age, was diagnosed with nuclear magnetic resonance imaging brain and. Prohance dosage: 15 Ml Once Iv. During the same period patient was treated with PRAVACHOL (View Pravachol Review and Pravachol Label ), CYMBALTA (View Cymbalta Review and Cymbalta Label ), TOPAMAX (View Topamax Review and Topamax Label ), GLUCOPHAGE (View Glucophage Review and Glucophage Label ), NEXIUM (View Nexium Review and Nexium Label ), GLUCOTROL (View Glucotrol Review and Glucotrol Label ), ZOCOR (View Zocor Review and Zocor Label ), PROTONIX (View Protonix Review and Protonix Label ). Patient was hospitalized.

5627065-3 | Blood Pressure Increased, Dyspnoea, Rales, Wheezing
Adverse event was reported on Jan 05, 2007 by a Female patient taking Prohance (View Usage) (Dosage: 15 Ml Once Iv) was diagnosed with nuclear magnetic resonance imaging, renal failure and. Location: UNITED STATES , 56 years of age, weighting 230.4 lb, After Prohance was administered, patient had the following side effects: blood pressure increased, dyspnoea, rales, wheezing.

5627064-1 | Cardiac Arrest, Chest Pain, Pulse Absent
on Jan 11, 2007 Male patient from UNITED STATES , 82 years of age, weighting 220.5 lb, was diagnosed with nuclear magnetic resonance imaging and was treated with Prohance (View Usage). Patient experienced the following unwanted or unexpected effects: cardiac arrest (What is cardiac arrest?), chest pain (What is chest pain?), pulse absent. Prohance dosage: 20 Ml Once Iv. During the same period patient was treated with LASIX SPECIAL (View Lasix Special Review and Lasix Special Label ), EASPRIN (View Easprin Review and Easprin Label ).

5627063-X | Dyspnoea, Lethargy, Pallor
on Jan 29, 2007 Male patient from UNITED STATES , 56 years of age, was diagnosed with choking sensation, nuclear magnetic resonance imaging and was treated with Prohance (View Usage). Patient had the following side effects: dyspnoea, lethargy, pallor. Prohance dosage: 20 Ml Once Iv.

5627062-8 | Anaphylactic Reaction
Patient was taking Prohance (View Usage). After Prohance was administered, patient had the following side effects: anaphylactic reaction on Mar 08, 2007 from UNITED STATES Additional patient health information: Male patient , 46 years of age, was diagnosed with back pain (What is back pain?), nuclear magnetic resonance imaging and. Prohance dosage: Iv. During the same period patient was treated with CENTRUM (View Centrum Review and Centrum Label ), FLEXERIL (View Flexeril Review and Flexeril Label ), PRINIVIL (View Prinivil Review and Prinivil Label ), HYDRODIURIL (View Hydrodiuril Review and Hydrodiuril Label ), DILAUDID (View Dilaudid Review and Dilaudid Label ).

5627061-6 | Hypersensitivity
Adverse event was reported on Mar 23, 2007 by a Female patient taking Prohance (View Usage) (Dosage: Iv) was diagnosed with nuclear magnetic resonance imaging and. Location: UNITED STATES , 28 years of age, Patient experienced the following unwanted or unexpected effects: hypersensitivity.

5627060-4 | Anaphylactic Reaction, Depressed Level Of Consciousness, Hypotonia, Loss Of Consciousness, Urticaria
on Apr 04, 2007 Female patient from UNITED STATES , 83 years of age, was diagnosed with transient ischaemic attack and was treated with Prohance (View Usage). Patient had the following side effects: anaphylactic reaction, depressed level of consciousness, hypotonia, loss of consciousness, urticaria. Prohance dosage: 20 Ml Once Iv.

5627059-8 | Cyanosis, Dyspnoea, Sneezing, Throat Irritation
on Mar 30, 2007 Female patient from UNITED STATES , child 4 years of age, was diagnosed with brain neoplasm, nuclear magnetic resonance imaging brain and was treated with Prohance (View Usage). After Prohance was administered, patient had the following side effects: cyanosis, dyspnoea, sneezing, throat irritation. Prohance dosage: 15 Ml Once Sy.

5627055-0 | Anaphylactic Shock
Patient was taking Prohance (View Usage). Patient experienced the following unwanted or unexpected effects: anaphylactic shock on Jun 14, 2007 from UNITED STATES Additional patient health information: Female patient , 31 years of age, was diagnosed with nuclear magnetic resonance imaging brain and. Prohance dosage: 20 Ml Once Iv. Patient was hospitalized.

5627053-7 | Anaphylactic Reaction
Adverse event was reported on Jun 28, 2007 by a Female patient taking Prohance (View Usage) (Dosage: 60 Ml Once Iv) was diagnosed with intermittent claudication and. Location: UNITED STATES , 68 years of age, Patient had the following side effects: anaphylactic reaction.

5627044-6 | Anaphylactic Reaction
on Jul 17, 2007 Female patient from UNITED STATES , 33 years of age, weighting 154.3 lb, was diagnosed with nuclear magnetic resonance imaging brain and was treated with Prohance (View Usage). After Prohance was administered, patient had the following side effects: anaphylactic reaction. Prohance dosage: 15 Ml Once Iv.

5627041-0 | Hypersensitivity
on Aug 20, 2007 Male patient from UNITED STATES , 40 years of age, was diagnosed with nuclear magnetic resonance imaging and was treated with Prohance (View Usage). Patient experienced the following unwanted or unexpected effects: hypersensitivity. Prohance dosage: 20 Ml Once Iv.

5627039-2 | Hypersensitivity
Patient was taking Prohance (View Usage). Patient had the following side effects: hypersensitivity on Sep 27, 2007 from UNITED STATES Additional patient health information: Female patient , 64 years of age, was diagnosed with nuclear magnetic resonance imaging brain and. Prohance dosage: 12 Ml Once Iv. Patient was hospitalized.